Eri Nanizawa

Eri Nanizawa

Auto-generated profile, based on publicly available information

Eri Nanizawa

Department of Anatomy, Aichi Medical University, Nagakute-city, Aichi, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CSChiharu Suzuki
Chiharu Suzuki
NHNaoyuki Hatayama
Naoyuki Hatayama
TOTadashi Ogawa
Tadashi Ogawa
ENEri Nanizawa
Eri Nanizawa
SOShun Otsuka
Shun Otsuka
SHShuichi Hirai
Shuichi Hirai
The high-pressure gas (HPG) method with carbon monoxide (CO) and oxygen (O2) mixture maintains the preserved rat heart function. The metabolites of rat hearts preserved using the HPG method (HPG group) and cold storage (CS) method (CS group) by immersion in a stock solution for 24 h were assessed to confirm CO and O2 effects. Lactic acid was significantly lower and citric acid was significantly higher in the HPG group than in the CS group. Moreover, adenosine triphosphate (ATP) levels as well as some pentose phosphate pathway (PPP) metabolites and reduced nicotinamide adenine dinucleotide phosphate (NADPH) were significantly higher in the HPG group than in the CS group. Additionally, reduced glutathione (GSH), which protects cells from oxidative stress, was also significantly higher in the HPG group than in the CS group. These results indicated that each gas, CO and O2, induced the shift from anaerobic to aerobic metabolism, maintaining the energy of ischemic preserved organs, shifting the glucose utilization from glycolysis toward PPP, and reducing oxidative stress. Both CO and O2 in the HPG method have important effects on the ATP supply and decrease oxidative stress for preventing ischemic injury. The HPG method may be useful for clinical application.


18 December 2024 in BMC Nutrition
Verified
Journal Article
Open access
PDF file
ENEri Nanizawa
Eri Nanizawa
YTYuki Tamaki
Yuki Tamaki
TYTomiko Yakura
Tomiko Yakura
SOShun Otsuka
Shun Otsuka
NHNaoyuki Hatayama
Naoyuki Hatayama
MNMunekazu Naito
Munekazu Naito
Recently, the number of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and its more advanced condition, metabolic dysfunction-associated steatohepatitis (MASH), has been increasing. These patients are at a higher risk of cardiovascular events and thromboembolism. However, the direct impact of high-fat diet (HFD), a cause of MASLD, on liver coagulation function is not well understood. Previously, we demonstrated that a short-term, 4-day intake of a HFD exacerbates concanavalin A (Con A)-induced acute liver injury in mice by promoting coagulation and inflammation. This model demonstrates that the liver exposed to a short-term HFD is vulnerable even before disease onset. In this study, using this model, we elucidated the detailed mechanisms by which short-term HFD intake promotes coagulation, considering primary and secondary hemostasis. C57BL/6 mice normally fed a normal diet (ND) were subjected to a HFD for 4 days. Liver tissue and blood samples were collected before and 4 and 24 h after Con A administration. Histological analysis, flow cytometry for platelet analysis, and blood coagulation tests related to secondary hemostasis were performed. Even with short-term consumption of a HFD alone, platelet and fibrinogen levels increased in the peripheral blood and liver. Additionally, when Con A was administered to mice on a short-term HFD, an increase in P-selectin expression was observed in the liver, with no upregulation in peripheral blood platelets. Furthermore, in mice subjected to a short-term HFD and treated with Con A, prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT) were observed. Consuming a HFD in short-term can enhance primary and secondary hemostasis, thereby increasing the risk of thrombosis. These conditions are presumed to be a risk factor that exacerbates Con A-induced liver injury. The findings provide insight into early intervention strategies for chronic liver diseases, such as MASLD and MASH.

5 August 2025 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
ENEri Nanizawa
Eri Nanizawa
YKYuki Katoh
Yuki Katoh
YTYuki Tamaki
Yuki Tamaki
SOShun Otsuka
Shun Otsuka
NHNaoyuki Hatayama
Naoyuki Hatayama
MNMunekazu Naito
Munekazu Naito